Frequently Asked Questions

NADairX® is a pulmonary-delivered NAD⁺ nutraceutical platform designed to support cellular energy, resilience and performance. It delivers pharmaceutical-grade NAD⁺ via inhalation, leveraging respiratory physiology to provide systemic access while bypassing gastrointestinal breakdown and first-pass liver metabolism. It is designed for consistent, repeatable exposure within an evidence-led framework.

Traditional oral supplements must pass through the gastrointestinal tract and liver, where enzymatic breakdown and metabolic processing can reduce available compound. NADairX® utilises pulmonary delivery to bypass this route, offering an alternative access pathway without injectable infrastructure. NADairX® is fast, non-invasive, and highly bioavailable - combining the best of both worlds.

NADairX® is positioned as a nutraceutical wellness product. It is not a licensed medicinal product and is not intended to diagnose, treat or cure disease. Its formulation, claims and positioning are structured within nutraceutical regulatory boundaries.

L-Leucine is the most widely used DPI excipient among all amino acids, leucine is the most frequently utilised for modifying the surface of DPI formulations and is generally considered safe and widely accepted as a formulation excipient.

The lungs provide one of the most efficient systemic access surfaces in human physiology. The alveolar region contains an extensive capillary network and a large surface area designed for rapid molecular exchange. When appropriately sized particles are inhaled, they can deposit within the respiratory tract and enter circulation without undergoing gastrointestinal degradation or first-pass hepatic metabolism.

Unlike oral supplementation, pulmonary delivery leverages direct respiratory exchange pathways. This route has been used for decades in medical inhalation technologies. NADairX® applies this established delivery principle within a nutraceutical framework, enabling repeatable exposure without the infrastructure required for injectable administration.

The alveoli provide an estimated 60-80 m² of exchange surface area, supported by a dense capillary network and an ultra-thin epithelial barrier optimised for molecular diffusion. This structure allows small particles, when correctly engineered, to interact efficiently with systemic circulation pathways.

Pulmonary delivery bypasses gastric pH degradation, intestinal transport limitations and hepatic first-pass metabolism. This does not inherently imply superiority, but it represents a distinct and physiologically rational route of administration.

Particle size plays a critical role in deposition location within the respiratory tract. Larger particles tend to deposit in the upper airways, while smaller particles may travel deeper into the bronchial and alveolar regions.

NADairX® is formulated with controlled particle size distribution to support targeted deposition dynamics consistent with established dry powder inhalation principles. Deposition behaviour is influenced by inhalation flow rate, airway geometry and formulation characteristics.

NAD⁺ is an endogenous co-enzyme continuously synthesised, utilised and recycled within human cells. Once absorbed, it participates in established cellular pathways and is metabolised through normal biochemical processes.

Because NAD⁺ is a biological molecule already present in the body, it does not function as an inert foreign substance. It does not persist as a structural residue within lung tissue when delivered in appropriate form. Normal mucociliary clearance mechanisms support respiratory homeostasis.

Intravenous administration delivers compounds directly into systemic circulation under medical supervision. Pulmonary delivery relies on respiratory exchange pathways and diffusion across the alveolar membrane.

Both routes bypass gastrointestinal metabolism. However, they differ in pharmacokinetic profile, administration context and regulatory classification. NADairX® is positioned as a non-injectable nutraceutical alternative designed for accessibility and consistency rather than acute clinical intervention.

NAD⁺ participates in dynamic cellular processes related to energy metabolism, redox balance and enzymatic activity. Physiological systems often respond to steady substrate availability differently from intermittent high-concentration exposure.

NADairX® is designed around the principle of tolerability and repeatability, supporting consistent access within a real-world performance framework rather than episodic medicalised intervention.

Route of administration alone does not determine regulatory classification. Classification depends on formulation, claims and intended use. Pulmonary delivery is a well-characterised physiological pathway. NADairX® applies this delivery route within nutraceutical positioning and avoids medicinal claims.

Nicotinamide adenine dinucleotide (NAD⁺) is a naturally occurring co-enzyme found in every living cell. It plays a central role in mitochondrial function, cellular metabolism and ATP production. NAD⁺ levels are known to decline with age and physiological stress.

NAD⁺ is a naturally produced co-enzyme that the body synthesises and utilises continuously as part of normal cellular function. Because it is endogenous to human biology, the body is already equipped with pathways to metabolise and use it.

NADairX® uses dry powder inhalation technology based on established respiratory delivery mechanisms that have been used safely in medical applications for decades. NAD⁺ is absorbed and utilised by the body rather than accumulating - it does not persist as residue in the lungs.

As with any inhaled product, some individuals may experience mild throat dryness or transient cough. Individuals with respiratory conditions or complex medical histories should consult a healthcare professional before use.

Due to its NaCl (salt) content, NADairX may also act as a mild mucolytic, helping to loosen and clear mucus from the airways.

Most users report good tolerability. As with other inhaled dry powder products, mild throat dryness or temporary irritation may occur. If discomfort persists, discontinue use and seek professional advice.

NADairX contains pharmaceutical-grade sodium chloride (salt), similar to ingredients commonly used in salt therapy environments. Salt particles may help loosen existing mucus in the airways, which can lead to temporary coughing, throat clearing, or mucus expulsion as the body naturally clears the respiratory tract. This effect is typically mild and short-term. The amount of salt in each dose is similar to that of a 15 minute salt session.

Individuals who are pregnant, breastfeeding, under 18, or managing respiratory or complex medical conditions should consult a qualified healthcare provider prior to use. Those with active respiratory infections should delay use until recovered. Those currently under medical supervision such as cancer treatment should seek medical advice prior to use.

NAD⁺ is a naturally occurring biological molecule and is not included on the current World Anti-Doping Agency Prohibited List. Elite athletes remain responsible for verifying compliance with their governing body and sport-specific regulations before use.

Because NAD⁺ is endogenous and not prohibited, it may be suitable within professional sport frameworks. Athletes should confirm usage within their team or federation compliance structures.

Insert a size-3 capsule into the device chamber and activate according to instructions. Inhale steadily and deeply. If visible residue remains after use, perform two additional inhales without a capsule inserted to clear the chamber fully.

Usage frequency depends on your chosen protocol and guidance. NADairX® is designed for consistent, repeatable exposure rather than sporadic high-dose interventions.

IV NAD⁺ is administered intravenously in a clinical setting. NADairX® provides pulmonary delivery designed for personal use. These are different access routes with different practical and experiential considerations. NADairX® is positioned as a complementary access point rather than a replacement for supervised IV protocols.

NAD⁺ plays a recognised role in cellular biology and ageing research. NADairX® is positioned as a nutraceutical product designed to support vitality and performance. It does not claim to treat or prevent age-related disease.

Individual experiences vary. Some users report immediate clarity or energy support, while others notice gradual effects over consistent use.

Regulatory classification depends on formulation, intended use and claims rather than route of administration alone. NADairX® is carefully positioned within nutraceutical boundaries and does not make medicinal claims.

NADairX® is not a licensed medicinal product. It is manufactured in line with applicable standards but does not require prescription authorisation.

Yes - NADairX devices are manufactured in accordance with internationally recognised quality management standards.

Yes - NADairX devices are CE marked.This confirms that the product meets required standards for safety, health, and environmental protection, and has been assessed in accordance with relevant regulatory frameworks.

Store in a cool, dry environment away from direct sunlight and moisture.

In most cases, yes. Users should check local customs regulations regarding nutraceutical products before international travel.